

## ARGENICA RECEIVES \$1.38M R&D TAX INCENTIVE CASH REFUND FOR FY22

**Perth, Australia; 4 October 2022** – Argenica Therapeutics Limited (Argenica or Company) (ASX: AGN) is pleased to advise that it has received a cash refund of \$1,377,917 from its R&D tax incentive claim for the financial year ending 30 June 2022. The Australian Federal Government’s R&D Tax Incentive Program provides a cash refund on eligible research and development activities performed by Australian companies.

Argenica CEO, Liz Dallimore, commented “The R&D Tax Incentive Program is an important program that strongly supports Australian innovation. These funds will be applied to further developing the Company’s lead neuroprotective peptide candidate, ARG-007, which has been successfully demonstrated to improve outcomes in preclinical stroke and HIE models and will shortly commence a Phase 1 clinical trial in healthy human volunteers to test its safety and tolerability.”

*This announcement has been approved for release by the Managing Director & Company Secretary.*

For more information please contact: [info@argenica.com.au](mailto:info@argenica.com.au)

### ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after neurological injuries and improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007 has been successfully demonstrated to improve outcomes in preclinical stroke and HIE models and will shortly commence a Phase 1 clinical trial in healthy human volunteers to test its safety and tolerability. The aim is for our therapeutic to be administered by first responders to protect brain tissue against damage during a stroke and other types of brain injury, including HIE, with further potential to enhance recovery once a brain injury has taken place.